ZHEJIANG HAISEN PHARMACEUTICAL CO., LTD.

Zhejiang Haisen Pharmaceutical Co., Ltd.

001367

CNE1000061L9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
23.34 ^CNY	+1.13%		-5.62%	-21.42%

06-11	Zhejiang Haisen Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for 2023, Payable on June 18, 2024	CI
05-20	Zhejiang Haisen Pharmaceutical Co., Ltd. Approves 2023 Profit Distribution Plan	CI

Zhejiang Haisen Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for 2023, Payable on June 18, 2024

June 10, 2024

Zhejiang Haisen Pharmaceutical Co., Ltd. 2023 final profit distribution plan to be implemented on A shares: The company announced Cash dividend/10 shares (tax included) of CNY 5.00000000 on (A shares) for year 2023. Payment date: June 18, 2024, Record date: June 17, 2024, Ex-date: June 18, 2024.

Latest news about Zhejiang Haisen Pharmaceutical Co., Ltd.

Zhejiang Haisen Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for 2023, Payable on June 18, 2024	06-10	CI
Zhejiang Haisen Pharmaceutical Co., Ltd. Approves 2023 Profit Distribution Plan	05-20	CI
Zhejiang Haisen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Zhejiang Haisen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-22	CI
Certain A Shares of Zhejiang Haisen Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 10-APR-2024.	04-09	CI
Zhejiang Haisen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Zhejiang Haisen Pharmaceutical Co., Ltd. Announces Directorate Appointments	23-09-28	CI
Haisen Pharmaceutical to Invest 3 Billion Yuan on New Factory	23-09-19	MT
Cheng Yi Pharmaceutical Gains Nod to Market Osteoarthritis Drug Ingredient	23-09-19	MT
Zhejiang Haisen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Zhejiang Haisen Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 756.16 million.	23-04-03	CI
Zhejiang Haisen Pharmaceutical Co., Ltd. has filed an IPO.	23-02-20	CI

Chart Zhejiang Haisen Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Haisen Pharmaceutical Co., Ltd.

More charts

Company Profile

Zhejiang Haisen Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical active pharmaceutical ingredient (APIs) and intermediates. The Company's main drugs include digestive system drugs, antipyretic and analgesic drugs, cardiovascular APIs, antidepressants drugs, antibacterial APIs, antiviral drugs, non-steroidal anti-inflammatory and other specialty APIs and preparations. The Company mainly conducts its businesses in domestic and overseas markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG HAISEN PHARMACEUTICAL CO., LTD.	-21.42%	323M
ELI LILLY AND COMPANY	+55.32%	815B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B